DUAKLIR PRESSAIR
LAMALABA DPI
Aclidinium bromide / Formoterol fumarate · Covis Pharma (an Azurity Pharmaceuticals company)
Active Medication & Mechanism
- Aclidinium bromide LAMA400 mcg per actuation (delivers 396 mcg from mouthpiece)
Long-acting muscarinic antagonist. Blocks M3 receptors on airway smooth muscle, reducing cholinergic bronchoconstriction. Rapidly hydrolyzed in plasma, reducing systemic anticholinergic effects.
- Formoterol fumarate dihydrate LABA12 mcg per actuation
Long-acting beta2-adrenergic agonist with rapid onset. Relaxes bronchial smooth muscle via beta2-receptor stimulation.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
400/12 mcg
1 inhalation twice daily (morning and evening) → 800/24 mcg
FDA Approved
Long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.
Not Approved
Duaklir Pressair is NOT indicated for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
400/12 mcg 1 inhalation twice daily (morning and evening) → 800/24 mcg
COPD FDA Approved
Long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.
Asthma Not Approved
Duaklir Pressair is NOT indicated for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for relief of acute bronchospasm. Use a SABA.